• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    The 11 Steps of Metrology Matching

    Realizing the Promise of Pre-Validated Packaging

    Creating a Natural Extension: Instrument Manufacturing

    Squeaky Clean: Orthopedic Device Packaging & Sterilization

    Natural Selection: Biologics in Orthopedics
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Stimwave Responds to Nevro Patent Lawsuit

    Medbio Acquires AIM Plastics

    Renowned Surgeon Appointed to Intellijoint Surgical’s Scientific Advisory Board

    Prosthetic Restores Sense of Where the Hand Is

    SeaSpine Appoints Two New Board Members
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    Stimwave Responds to Nevro Patent Lawsuit

    Renowned Surgeon Appointed to Intellijoint Surgical’s Scientific Advisory Board

    Prosthetic Restores Sense of Where the Hand Is

    SeaSpine Appoints Two New Board Members

    Polymer Twin: New Implant Imitates Bone Structure
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Fostering Breakthrough Device Development

    Strengthening Muscular Rehabilitation with Objective Clinical Data

    Nail Simplifies Two-Procedure Rotator Cuff Repair

    Treating that Pain-in-the-Neck Smartphone

    Sounding Board: 2018 Reflections and Looking Ahead
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Medbio Inc.

    Atlas Vac Machine

    Cadence Inc.

    Five Star Manufacturing Inc.

    Donatelle
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    Setting Transaction Process Expectations: Strategic vs. Financial Buyers

    Brian Gorski, Vice President, P&M Corporate Finance11.22.16
    Much time has been spent analyzing M&A and consolidation trends impacting the medical device and manufacturing industries, and rightfully so. As transaction multiples remain strong and high-quality and well-heeled buyers continue to execute aggressive acquisition strategies, M&A announcements have seemingly become part of the everyday news cycle in our industry. Analyzing transaction metrics and speculating on what the next “big deal” will be is topnotch water cooler material—and for owners considering selling their businesses, a post-game focus and analysis is exceedingly helpful in setting valuation expectations and handicapping potential buyers. However, an area that doesn’t get much attention and is widely considered to be merely “procedural” is the transaction process—the set of activities required to complete these industry-shaping M&A deals. 

    Once the decision has been made to sell, many business owners typically have a predetermined view on selling to a strategic buyer versus selling to a financial buyer. While this direction is helpful in shaping the universe of potential buyers, oftentimes owners don’t fully realize the processes involved in selling to a strategic buyer versus a financial buyer can be quite different. A more complete “game planning” discussion on what to expect during the transaction process with each set of buyers is most certainly warranted, but in this piece we will attempt to provide some insight on transaction structuring, due diligence, and transaction approval and closing.

    Transaction Structuring
    Although the headline in most M&A transaction negotiations is purchase price, much more must be considered when deciding on a transaction partner. Having a sense of what to expect from strategic and financial buyers on key terms such as form of consideration (cash vs. stock), contingent consideration (earn-outs), management compensation/non-competes, required equity roll-over, financing contingencies, and indemnification packages should help to avoid any surprises and set expectations. We’ve compiled some observations from recent transaction experiences:

    Strategic Buyer Tendencies
    • The ability to enjoy immediate synergies (both revenue and operational), as well as the strategic benefits (product line expansion, customer acquisition, geographic extension) allows strategic buyers to pay more than a financial buyer in many instances.
    • With strategic buyers, business owners are most often selling 100 percent of their company. Depending on the buyer and transaction structure, the seller is often asked to take some stock in the combined entity as part of the overall transaction consideration. This allows for some post-transaction risk-sharing for the buyer, as well as for the seller to participate in some “upside” of the combined entity.
    • Key managers are often retained on “like terms” as existing management teams, with opportunities for investment in the new or combined company limited when compared to opportunities with financial buyers. While exceptions can always be made, the salaries, titles, and benefits of key managers are often adjusted to align with the corporate policies of the buyer.
    • With board-level sign-off required for most acquisitions, strategic buyers are often unable to meaningfully alter transactions’ structures to bridge negotiation gaps without first gaining formal approval from the board.
    Financial Buyer Tendencies
    • Competing with strategic buyers on valuation is challenging for financial buyers for various reasons, though primarily due to the inability to realize the immediate synergies that strategic buyers will enjoy as well as the need to use third-party financing to pay for the acquisition.
    • Financial buyers are in the business of executing transactions, and can often be more flexible than a strategic buyer to meet a seller’s needs. Features such as earn-outs and equity co-investments are examples of levers financial buyers can pull to bridge valuation gaps and provide more upside to a seller.
    • The speed at which most financial buyers gain approval and provide feedback is a key differentiator when compared to most strategic buyers. Sellers and their transaction advisors are often working directly with the decision-maker at a financial buyer, allowing for expedient feedback and decision-making.
    Due Diligence
    Once key transaction terms have been agreed upon between the buyer and seller, there is still much work to be done before closing the transaction. A letter-of-intent containing an exclusivity clause for the buyer as well as a detailed due diligence plan (among other items) is then negotiated and signed. This due diligence plan should include a detailed timeline and a roster of the diligence team (financial, environmental, insurance, regulatory, customer, legal, commercial, etc.). Executing transaction diligence typically requires the involvement of the seller’s executive management team as well the next level of managers to gather information and answer follow-up questions. The timeliness and organization of the due diligence process is crucial to maintaining the confidentiality of discussions and minimizing disruptions to the daily operations of the business, and can vary widely between strategic and financial buyers.

    Strategic Buyer Diligence Execution
    • Generally speaking, strategic buyers do not have a team dedicated to executing diligence; rather, they take a “diligence by committee” approach by leveraging internal resources. In the absence of a corporate (or business) development manager, the onus often falls on the chief financial officer to quarterback this process. This less-structured approach can often result in unexpected scheduling delays as business travel and other pre-scheduled meetings, conferences, and even paid time off can make scheduling on-site meetings more cumbersome.
    • Although it is standard procedure, sellers often have concerns providing strategic buyers unfettered access to sensitive information such as pricing data, margins, intellectual property, and customer lists. Strategic buyers are privy to this data regardless of a deal’s outcome.
    • Validating historical and projected financial performance is perhaps the most critical component of the due diligence process. However, strategic buyers spend nearly an equivalent amount of time examining and pressure testing cost accounting and operational metrics such as standards for setting overhead, material, and labor rates, and measuring and validating manufacturing throughput and efficiencies.
    • For obvious reasons, most sellers prefer to keep the news that their business is up for sale confidential and limited to a few key managers and advisors. This is increasingly difficult as the president, CEO, or sales head from the buyer are on-site for facility tours and other diligence meetings. As opposed to financial buyers (whose visits can be explained as consultants, accountants, or lenders), the presence of top-level industry executives at a seller’s facility makes keeping a potential transaction under wraps more challenging.
    Financial Buyer Diligence Execution
    • At their core, financial buyers are dealmakers; as such, efficiently executing transactions is a key core competency and differentiator when compared to strategic buyers. The value of speed and certainty of closing with a well-established financial buyer should not be underestimated.
    • As opposed to a strategic buyer, most financial buyers outsource the majority of their diligence work to third parties who specialize in transactional due diligence. Separate teams of financial, environmental, legal, insurance, and human resources experts will be engaged by the financial buyer to perform targeted diligence exercises. In most cases, the financial buyer and the seller’s advisor will conduct most of the information gathering and interfacing with diligence providers in an effort to limit daily disruptions to the seller and ensure a well-choreographed execution.
    • During the diligence period, financial buyers tend to be more focused on the month-to-month financial performance of the company than strategic buyers. This is primarily due to the underwriting requirements of the lender(s) that will be used to finance the purchase, and their reliance on trailing-twelve-month financial metrics used to calculate the level of debt lenders are comfortable providing for the purchase. In addition, a separate set of meetings between the company and lenders is often required to secure financing.
    Transaction Approval and Closing
    Upon completion of due diligence and the negotiation and finalization of the requisite deal documents to formalize the transaction terms, the approval of various parties is required before documents are signed and funds transferred. This approval process varies widely from buyer to buyer, but can lead to unanticipated delays and transaction anxiety if the approval process is not clearly discussed and understood upfront.

    Strategic Buyer Approval Process
    • Strategic buyers often require formal board approval before an acquisition officially closes. The timing of this approval can be obtained at any point throughout the transaction process—understanding the nuances of this process is critical in avoiding unanticipated delays. With larger strategic buyers, this approval often can only be obtained during quarterly board meetings or at other pre-scheduled corporate assemblies.
    • Deal financing is often provided by a strategic buyer’s existing lenders, eliminating the need for a separate credit approval process. While smaller strategic buyers may need to be mindful of tripping covenants or over-leveraging, many larger strategic buyers have credit facilities in place specifically designated for M&A activity.
    • In most transactions, as a condition of closing, buyers will require calls with key customers to obtain their opinion of their relationship with the seller. Additionally, the buyer will look for assurances from the customer that the relationship will continue post-transaction and that key programs and supply agreements will remain unchanged. While the risk of a customer pulling work or meaningfully altering a relationship as a result of an acquisition is low, there have been rare instances where buyers need more time to think through the feedback received through customer calls.
    Financial Buyer Approval Process
    • As previously mentioned, one of the benefits of working with a financial buyer is the ability to quickly make decisions, including the final approval of a transaction post-due diligence. In many cases, the investment committee will have pre-approved the transaction, provided no material adverse findings arise during the diligence process.
    • If meaningful issues arise with due diligence or unexpected material changes in the business (losing a customer or key program) transpire, financial buyers can usually find a path to a successful transaction. Aside from their belief in the business model and excitement about partnering with the company, one of the main motivators for financial buyers to complete a transaction is to avoid dead deal expenses. Unlike strategic buyers, who largely leverage internal resources to execute diligence, financial buyers spend hundreds of thousands of dollars with the third-party diligence providers previously discussed. That being said, walking away from a bad deal will clearly be more cost effective than eating dead deal expenses.  
    • Underwriting approval delays from the lending partners of financial buyers is one of the few reasons for unexpected delays in transaction approval and closing post-due diligence from financial buyers. Despite separate lender meetings, due diligence requests, and timely communication of financial and business updates, lender approval can be delayed occasionally for reasons beyond the control of the buyer or seller.
    The process involved in selling a business the right way is complex and involves many parties collaborating on countless work streams in order to reach a common goal. While the dynamics are different for every situation and buyer, this column hopefully provided a range of potential scenarios and questions that should be asked initially to avoid surprises. Ensuring that everyone’s eyes are wide open and on the same page before getting into the throes of a deal will undoubtedly make an arduous process a little less painful for all parties involved. 


    Brian Gorski is a vice president with PMCF and a member of the firm’s medical technology team. He has more than 12 years of transaction advisory experience, having advised public and private companies on merger and acquisition mandates, valuation matters, private placements and financing transactions. He can be reached at brian.gorski@pmcf.com.
    Related Searches
    • testing
    • president
    • technology
    • medical device

    Related Columns

    • An Industry on the Defensive

      An Industry on the Defensive

      It’s been a rough six months for the medtech industry. Nearly 200 days after it was first blindsided by a one-two punch of bad publicity from the damning Netflix documentary “The Bleeding Edge,” the sector remains firmly immersed…
      Michael Barbella, Managing Editor 02.13.19

    • Medtech and The Management Top 250

      Medtech and The Management Top 250

      Developed by the Drucker Institute and publicized by The Wall Street Journal, The Management Top 250 Ranking measures and ranks corporate competencies from 1-250 by scrutinizing operations in five areas: customer satisfaction, employee engagement and…
      Maria Shepherd, President and Founder, Medi-Vantage 02.13.19

    • 3-D Printing/Additive Mfg.
      The Gawky Teenage Phase: 3D Printing Enters Adolescence

      The Gawky Teenage Phase: 3D Printing Enters Adolescence

      As the mom of a young teen, I get a daily, real-time view of the of the challenges of a human doing his best to grow up. There are a lot of false starts, half-baked ideas, and epic fails, but there’s also tremendous potential and frequent victo…
      Dawn A. Lissy, President & Founder, Empirical 02.13.19


    • 3-D Printing/Additive Mfg. | Biologics | MIS/Robotics
      Getting a Clinical Viewpoint

      Getting a Clinical Viewpoint

      Last year, at the North American Spine Society’s (NASS) 33rd Annual Meeting, held in Los Angeles, Jeffrey C. Wang, M.D., professor of orthopaedic surgery and neurological surgery (clinical scholar) at the Keck Medical Center at the University o…
      Sean Fenske, Editor-in-Chief 02.13.19

    • Design | Research & Development
      Trial Master File: Paper or Electronic?

      Trial Master File: Paper or Electronic?

      The Trial Master File (TMF) is the central location for all clinical trial documents. From the start of a clinical trial through its conclusion, the TMF contains and secures a variety of information such as signature pages, study logs, ethics committ…
      Anuradha Nagulapati, Clinical Research Associate, Musculoskeletal Clinical Regulatory Advisers 02.13.19

    • Software & Quality
      2019: The Year to Enhance Quality in Orthopedic Product Development

      2019: The Year to Enhance Quality in Orthopedic Product Development

      The world has gone digital, and now it’s time for orthopedic product developers and manufacturers to catch up. According to LNS Research, 60 percent of all organizations are investing in industrial transformation—otherwise known as digita…
      Anthony Parise, Product Strategist—Life Sciences, ETQ 02.13.19


    • Biologics | MIS/Robotics | Trauma/Sports
      Global Prospects in Orthopedics

      Global Prospects in Orthopedics

      Camil Moldoveanu was fully prepared for the challenge. Or so he thought. The four-time Brazilian jiu-jitsu world champion knew he would need significant rehabilitation for his knee injury. He also knew the recovery process would be difficult, and…
      Michael Barbella, Managing Editor 11.30.18

    • Spine/Neurology
      Leveraging Innovation to Address the Opioid Crisis

      Leveraging Innovation to Address the Opioid Crisis

      The news has been devastating; according to the National Institute on Drug Abuse (NIDA) website, “every day, more than 115 people in the United States die after overdosing on opioids…including prescription pain relievers, heroin, and syn…
      Maria Shepherd, President and Founder, Medi-Vantage 11.30.18

    • Design | Research & Development
      MPO Summit: The View from the Top

      MPO Summit: The View from the Top

      It started with a wintry dusting of snow and ended in a blaze of autumnal glory. On top of a mini tour of Colorado’s best seasons, the two-day MPO Summit in Broomfield on Oct. 11-12 offered forecasts and insights into what it takes to weather c…
      Dawn A. Lissy, President & Founder, Empirical 11.30.18


    • MDSAP Audits Update: Progress, Challenges, and a Cost Reduction Case Study

      MDSAP Audits Update: Progress, Challenges, and a Cost Reduction Case Study

      The Medical Device Single Audit Program (MDSAP) is growing fast, with 3,629 sites now participating, as compared to just 788 at the end of 2017. Part of this explosive growth stems from the fact that Canada will require manufacturers to comply wit…
      Anthony Parise, Product Strategist—Life Sciences, ETQ 11.30.18

    • Data Monitoring Committees: Making DMCs Work for Your Study

      Data Monitoring Committees: Making DMCs Work for Your Study

      The use of independent data monitoring committees is becoming increasingly prevalent in the U.S. medtech industry. The FDA outlines these groups and their operation in a 12-year-old guidance due to expire at the end of this year. However, the composi…
      Margeaux Rogers, Senior Associate, Regulatory Affairs, Musculoskeletal Clinical Regulatory Advisers LLC 11.30.18

    • Top 10 Findings from a Warning Letter Analysis

      Top 10 Findings from a Warning Letter Analysis

      When I first started out in medtech, I did not have a good appreciation for quality systems. I was working as an engineer at the time, and I found quality systems quite a nuisance because any change I proposed was either restricted or not allowed due…
      Linda Braddon, Ph.D., President and CEO, Secure BioMed Evaluations 11.30.18

    • Extremities | Large Joint | Materials | Spine/Neurology
      Recycling Implanted Metals From Beyond the Grave

      Recycling Implanted Metals From Beyond the Grave

      Ever wonder what happens to devices implanted in the body after their users pass away? Probably not, because the thought of it tends to make most people who aren’t ODT editors cringe. But as medical implants become more common, people are dy…
      Sam Brusco, Associate Editor 09.19.18

    • MIS/Robotics
      Premium Medtech Price Stategies for the Orthopedic Robotics Segment

      Premium Medtech Price Stategies for the Orthopedic Robotics Segment

      Growth in the market for surgical robots used in hip and knee orthopedic procedures was forecasted at $222 million in 2015 with anticipated growth to reach $5 billion by 20221 (Table 1). A substantial number of next- generation robotic devices, syste…
      Maria Shepherd, President and Founder, Medi-Vantage 09.19.18

    • A Different Class of Engineer: How to Connect with Rising Medtech Talent

      A Different Class of Engineer: How to Connect with Rising Medtech Talent

      My grandfather—a World War II veteran who worked at GE in my native Cleveland—was one of my most beloved family members. When I told him I wanted to study engineering in college, he told me to find a university where I could get real, on-…
      Dawn A. Lissy, President & Founder, Empirical 09.19.18


    Breaking News
    • Stimwave Responds to Nevro Patent Lawsuit
    • Medbio Acquires AIM Plastics
    • Renowned Surgeon Appointed to Intellijoint Surgical’s Scientific Advisory Board
    • Prosthetic Restores Sense of Where the Hand Is
    • SeaSpine Appoints Two New Board Members
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • The 11 Steps of Metrology Matching
    • Realizing the Promise of Pre-Validated Packaging
    • Creating a Natural Extension: Instrument Manufacturing
    • Squeaky Clean: Orthopedic Device Packaging & Sterilization
    • Natural Selection: Biologics in Orthopedics
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login